MCID: CRB008
MIFTS: 43

Cerebral Atherosclerosis

Categories: Cardiovascular diseases

Aliases & Classifications for Cerebral Atherosclerosis

MalaCards integrated aliases for Cerebral Atherosclerosis:

Name: Cerebral Atherosclerosis 12 52 14 69
Intracranial Arteriosclerosis 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:12720
ICD10 33 I67.2
ICD9CM 35 437.0
MeSH 42 D002537
NCIt 47 C34459
UMLS 69 C0007775

Summaries for Cerebral Atherosclerosis

MalaCards based summary : Cerebral Atherosclerosis, also known as intracranial arteriosclerosis, is related to intracranial arteriosclerosis and cerebritis. An important gene associated with Cerebral Atherosclerosis is MTHFR (Methylenetetrahydrofolate Reductase), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and kidney, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 72 Cerebral atherosclerosis is a type of atherosclerosis where build-up of plaque in the blood vessels of... more...

Related Diseases for Cerebral Atherosclerosis

Diseases related to Cerebral Atherosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Related Disease Score Top Affiliating Genes
1 intracranial arteriosclerosis 12.0
2 cerebritis 10.6
3 atherosclerosis 10.6
4 microphthalmia, syndromic 9 10.3 APOE MTHFR
5 autoimmune hemolytic anemia, warm type 10.3 ACE APOE
6 hepatocellular adenoma 10.3 ACE MTHFR
7 iron metabolism disease 10.3 ACE APOE
8 hypertrichosis of eyelid 10.3 ACE MTHFR
9 cataract, autosomal dominant congenital 4 10.3 ACE APOE
10 joint disorders 10.3 ACE MTHFR
11 retinal arteries, tortuosity of 10.3 ACE APOE
12 bernard-soulier syndrome, type a2 10.3 ACE MTHFR
13 arthritis 10.3 ACE APOE
14 pelvic inflammatory disease 10.3 ACE MTHFR
15 familial osteochondritis dissecans 10.2 APOA1 APOE
16 fibular aplasia ectrodactyly 10.2 ACE RNF213
17 amelogenesis imperfecta, type iia3 10.2 APOA1 APOE
18 migraine with or without aura 1 10.2 APOA1 APOE
19 bird fancier's lung 10.2 APOA1 APOE
20 charcot-marie-tooth disease 10.2 APOE MTHFR
21 alzheimer disease-2 10.2 APOA1 APOE
22 chondrocalcinosis with early-onset osteoarthritis 10.2 APOA1 APOE
23 stone in bladder diverticulum 10.2 APOA1 APOE
24 priapism 10.1 APOE MTHFR
25 fuhrmann syndrome 10.1 MTHFR RNF213
26 diabetic encephalopathy 10.1 ACE APOE
27 pontocerebellar hypoplasia 10.1 APOA1 APOE
28 fish-eye disease 10.1 APOA1 APOE
29 periampullary adenoma 10.1 ACE APOE
30 hyperlipidemia, familial combined 10.1 APOA1 APOE
31 apolipoprotein c-iii deficiency 10.1 APOA1 APOE
32 wolfram syndrome 2 10.1 APOA1 APOE
33 ovarian clear cell malignant adenofibroma 10.1 APOA1 MTHFR
34 acute apical periodontitis 10.1 APOA1 APOE
35 obesity, hyperphagia, and developmental delay 10.1 APOA1 APOE
36 lissencephaly 6, with microcephaly 10.0 APOA1 APOE
37 unverricht-lundborg syndrome 9.9 RNF213 RPSA
38 intra-abdominal lymph node mast cell malignancy 9.9 ACE APOE MTHFR
39 carotid body cancer 9.9 ACE APOE MTHFR
40 stroke, ischemic 9.9 ACE APOE MTHFR
41 angina pectoris 9.8 ACE APOA1
42 melorheostosis 9.7 ACE APOA1 APOE
43 glossopharyngeal nerve disease 9.7 ACE APOA1 APOE
44 skin squamous cell carcinoma 9.7 ACE APOA1 APOE
45 myelophthisic anemia 9.7 ACE APOA1 APOE
46 hyperchylomicronemia, late-onset 9.7 APOA1 APOE
47 xanthogranulomatous pyelonephritis 9.5 ACE APOE MTHFR
48 heart disease 9.5
49 choroiditis 9.5
50 porphyria 9.5

Comorbidity relations with Cerebral Atherosclerosis via Phenotypic Disease Network (PDN): (show all 41)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchitis Bronchopneumonia
Cerebral Degeneration Cerebrovascular Disease
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypertensive Encephalopathy Hypoglycemia
Hypothyroidism Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Left Ventricular Outflow Tract Obstruction
Malignant Essential Hypertension Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Pseudobulbar Palsy
Schizophreniform Disorder Sinoatrial Node Disease
Status Epilepticus Swallowing Disorders
Transient Cerebral Ischemia Vascular Dementia
Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebral Atherosclerosis:



Diseases related to Cerebral Atherosclerosis

Symptoms & Phenotypes for Cerebral Atherosclerosis

GenomeRNAi Phenotypes related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.96 APOA1 APOE
2 Increased LDL uptake GR00340-A-1 8.62 APOA1 APOE

MGI Mouse Phenotypes related to Cerebral Atherosclerosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.35 APOE RNF213 RPSA ACE APOA1
2 endocrine/exocrine gland MP:0005379 9.02 ACE APOA1 APOE RNF213 RPSA

Drugs & Therapeutics for Cerebral Atherosclerosis

Drugs for Cerebral Atherosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
2
Cilostazol Approved Phase 4 73963-72-1 2754
3
Probucol Approved Phase 4 23288-49-5 4912
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8 Racepinephrine Approved Phase 4
9
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
10
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
11
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
12
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
13
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
14
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
15
Lisinopril Approved, Investigational Phase 4,Phase 3 83915-83-7, 76547-98-3 5362119
16
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
19
Ethanol Approved Phase 4 64-17-5 702
20
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
21
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
23
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2 59-67-6 938
24
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2 98-92-0 936
25
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
26
Angiotensin II Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
27 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
28 Antimetabolites Phase 4,Phase 3,Phase 2
29 Calcium, Dietary Phase 4,Phase 3,Phase 2
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
31 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
32 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
33 Rosuvastatin Calcium Phase 4 147098-20-2
34 Protective Agents Phase 4,Phase 2,Phase 3
35 Micronutrients Phase 4,Phase 3,Phase 2
36 Trace Elements Phase 4,Phase 3,Phase 2
37 Vitamins Phase 4,Phase 3,Phase 2
38 Fluorides Phase 4,Phase 2
39 Anti-Asthmatic Agents Phase 4
40 Antioxidants Phase 4,Phase 2,Phase 3
41 Autonomic Agents Phase 4,Phase 2
42 Bronchodilator Agents Phase 4
43 Fibrinolytic Agents Phase 4,Phase 3
44 Neuroprotective Agents Phase 4,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
46 Phosphodiesterase 3 Inhibitors Phase 4
47 Phosphodiesterase Inhibitors Phase 4
48 Platelet Aggregation Inhibitors Phase 4,Phase 3
49 Respiratory System Agents Phase 4
50 Vasodilator Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 201)

id Name Status NCT ID Phase Drugs
1 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Unknown status NCT02041117 Phase 4 Rosuvastatin
2 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
3 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
4 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
5 Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
6 Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes Completed NCT00847262 Phase 4 Temisartan;Amlodipine
7 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed NCT00130039 Phase 4 clopidogrel;Cilostazol
8 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
9 Atorvastatin in Acute Stroke Treatment Completed NCT02225834 Phase 4 Atorvastatin
10 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
11 Platelet Hyperreactivity to Aspirin and Stroke Completed NCT00766896 Phase 4 Aspirin (platelet sensitive versus platelet hyperreactivity)
12 Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients Completed NCT00449410 Phase 4 Atorvastatin;ezetimibe
13 Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study) Completed NCT00287508 Phase 4
14 Thyroid Hormone Replacement for Subclinical Hypothyroidism Completed NCT01660126 Phase 4 Levothyroxine;Placebo
15 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4 Amlodipine;Valsartan
16 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
17 Carotid Atherosclerosis Regression at Magnetic Resonance Assessment. Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
18 The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) Completed NCT01341730 Phase 4 Atorvastatin 20mg;Atorvastatin 20 mg + Pioglitazone 30 mg
19 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
20 Carotid Atherosclerosis: MEtformin for Insulin ResistAnce Study Completed NCT00723307 Phase 4 Metformin;Placebo
21 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
22 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Recruiting NCT02594800 Phase 4 Rosuvastatin
23 Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Recruiting NCT03248401 Phase 4 Cilostazol;Aspirin
24 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Recruiting NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
25 Preventive Effects of Ginseng Against Atherosclerosis Recruiting NCT02796664 Phase 4
26 Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus Recruiting NCT02162550 Phase 4 Bydureon;placebo
27 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques Recruiting NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
28 Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication Active, not recruiting NCT00715273 Phase 4 Atorvastatin;Niacin;Colesevelam;Placebo Niacin;Placebo Colesevelam
29 Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging Enrolling by invitation NCT02114697 Phase 4 Rosuvastatin
30 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Not yet recruiting NCT03252626 Phase 4 Alprostadil;Normal saline
31 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Not yet recruiting NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
32 Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis Terminated NCT01104311 Phase 4
33 Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI) Withdrawn NCT00388843 Phase 4
34 Effect Study of Modified Transoesophageal Echocardiography on Cerebral Embolization After Cardiothoracic Surgery Completed NCT01310608 Phase 3
35 EVA3S: Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis Completed NCT00190398 Phase 3
36 Cholesterol-Lowering Atherosclerosis Study (CLAS) Completed NCT00000599 Phase 3 colestipol;niacin
37 Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial Completed NCT01326676 Phase 3 Polypill: Red Heart Pill;Usual medication
38 Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes Completed NCT00116831 Phase 3 Glipizide;rosiglitazone maleate
39 Drug-eluting Balloon in Bifurcations Trial Completed NCT00857441 Phase 2, Phase 3
40 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
41 Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo) Completed NCT00361530 Phase 3 Statin
42 Effects of Lutein Supplementation on Subclinical Atherosclerosis Completed NCT01534533 Phase 2, Phase 3
43 Japan Statin Treatment Against Recurrent Stroke (J-STARS) Completed NCT00221104 Phase 3 Pravastatin
44 Atherosclerosis Monitoring and Atherogenicity Reduction Study Completed NCT01734707 Phase 3 Placebo
45 Endovascular Therapy for Acute Ischemic Stroke Trial Completed NCT02350283 Phase 3
46 Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis Completed NCT02133807 Phase 3
47 Women's Isoflavone Soy Health (WISH) Trial Completed NCT00118846 Phase 2, Phase 3
48 Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Completed NCT00526474 Phase 3 Vorapaxar;Placebo
49 Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Completed NCT00617123 Phase 3 Vorapaxar 2.5 mg;Placebo
50 ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial" Completed NCT00180518 Phase 2, Phase 3

Search NIH Clinical Center for Cerebral Atherosclerosis

Cochrane evidence based reviews: intracranial arteriosclerosis

Genetic Tests for Cerebral Atherosclerosis

Anatomical Context for Cerebral Atherosclerosis

MalaCards organs/tissues related to Cerebral Atherosclerosis:

39
Brain, Heart, Kidney, Smooth Muscle, Testes, Endothelial, Prostate

Publications for Cerebral Atherosclerosis

Articles related to Cerebral Atherosclerosis:

(show top 50) (show all 133)
id Title Authors Year
1
Differential impact of serum total bilirubin level on cerebral atherosclerosis and cerebral small vessel disease. ( 28319156 )
2017
2
Is obstructive sleep apnea associated with the presence of intracranial cerebral atherosclerosis? ( 28168435 )
2017
3
Proteomic analysis and comparison of intraa89 and extracranial cerebral atherosclerosis responses to hyperlipidemia in rabbits. ( 28677755 )
2017
4
Intake of antioxidants and B vitamins is inversely associated with ischemic stroke and cerebral atherosclerosis. ( 27698959 )
2016
5
Location of cerebral atherosclerosis: Why is there a difference between East and West? ( 27145795 )
2016
6
Value of higher-resolution MRI in assessing middle cerebral atherosclerosis and predicting capsular warning syndrome. ( 27080075 )
2016
7
A pathological perspective on the natural history of cerebral atherosclerosis. ( 25854637 )
2015
8
Letter by Tsuda regarding article, "Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction". ( 24448990 )
2014
9
Response to letter regarding article, "Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction". ( 24448989 )
2014
10
Susceptibility vessel signs on T2*-weighted gradient echo images in patients with cerebral atherosclerosis. ( 25231582 )
2014
11
Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction. ( 24021686 )
2013
12
Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. ( 23887837 )
2013
13
Nonrelevant cerebral atherosclerosis is a strong prognostic factor in acute cerebral infarction. ( 23686972 )
2013
14
Different impact of hyperhomocysteinemia on cerebral small vessel ischemia and cervico-cerebral atherosclerosis in non-stroke individuals. ( 23218488 )
2013
15
Elevated AI^42 in aged, non-demented individuals with cerebral atherosclerosis. ( 23919773 )
2013
16
Relationship between Cerebral Atherosclerosis and Leukoaraiosis in Aged Patients: Results from DSA. ( 24033698 )
2013
17
The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke. ( 21974846 )
2011
18
Gender differences in risk factors for intracranial cerebral atherosclerosis among asymptomatic subjects. ( 21497768 )
2011
19
Plasma total homocysteine and the methylenetetrahydrofolate reductase 677C>T polymorphism do not contribute to the distribution of cervico-cerebral atherosclerosis in ischaemic stroke patients. ( 20825473 )
2011
20
Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. ( 21350200 )
2011
21
Cerebral atherosclerosis causes neurodegenerative diseases. ( 20037498 )
2010
22
Classic risk factors for atherosclerosis are not major determinants for location of extracranial or intracranial cerebral atherosclerosis. ( 19169042 )
2009
23
Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 19560016 )
2009
24
Large vessel cerebral atherosclerosis is not in direct association with neuropathological lesions of Alzheimer's disease. ( 19521084 )
2009
25
Endothelial function in lacunar infarction: a comparison of lacunar infarction, cerebral atherosclerosis and control group. ( 19556769 )
2009
26
Risk factors of intracranial cerebral atherosclerosis among asymptomatics. ( 17690548 )
2007
27
Correlation of coronary and cerebral atherosclerosis: difference between extracranial and intracranial arteries. ( 16340186 )
2006
28
Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed! ( 16622698 )
2006
29
Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 16223717 )
2005
30
Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 16221663 )
2005
31
Intracranial angioplasty and stent placement for cerebral atherosclerosis. ( 15101521 )
2004
32
Cerebral atherosclerosis and oxidative stress in Alzheimer's disease. ( 14757939 )
2003
33
Cerebral atherosclerosis and mild Alzheimer's disease. ( 12855821 )
2003
34
Cerebral atherosclerosis causes neurogenic hypertension. ( 11988586 )
2002
35
Cerebral atherosclerosis and coronary calcification. ( 12364716 )
2002
36
Cerebral atherosclerosis as predictor of stroke and mortality in representative elderly population. ( 11779914 )
2002
37
Cerebral atherosclerosis occurs spontaneously in homozygous WHHL rabbits. ( 11368997 )
2001
38
Early lesions of cerebral atherosclerosis from induced hypertension in Watanabe heritable hyperlipidemic rabbits. ( 11193506 )
2000
39
The influence of the degree of cerebral atherosclerosis on the changes in hemostatic system in patients with ischemic brain disease and atherosclerotic encephalopathy. ( 10645149 )
1999
40
Cerebral atherosclerosis in Parkinsonian patients. ( 18591095 )
1998
41
Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. ( 9836754 )
1998
42
Race and sex differences in the distribution of cerebral atherosclerosis. ( 8898801 )
1996
43
Association between deletion polymorphism of the angiotensin-converting enzyme gene and cerebral atherosclerosis. ( 8704045 )
1996
44
Granule-laden perivascular cells observed in rabbits with experimental cerebral atherosclerosis. ( 8619506 )
1996
45
The lipoprotein profile of young adults with cerebral atherosclerosis. ( 9031424 )
1996
46
Enhancement of the intracranial arterial wall at MR imaging: relationship to cerebral atherosclerosis. ( 7824729 )
1995
47
The effects of hypertension on cerebral atherosclerosis in the cynomolgus monkey. ( 8342199 )
1993
48
Pattern of cerebral atherosclerosis in Hong Kong Chinese. Severity in intracranial and extracranial vessels. ( 8506547 )
1993
49
Pathology of cerebral atherosclerosis. Influence of age, race, and gender. ( 8249014 )
1993
50
Relative protection from cerebral atherosclerosis of young patients with homozygous familial hypercholesterolemia. ( 1799396 )
1991

Variations for Cerebral Atherosclerosis

Expression for Cerebral Atherosclerosis

Search GEO for disease gene expression data for Cerebral Atherosclerosis.

Pathways for Cerebral Atherosclerosis

GO Terms for Cerebral Atherosclerosis

Cellular components related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.46 APOA1 APOE
2 extracellular matrix GO:0031012 9.43 APOE RPSA
3 high-density lipoprotein particle GO:0034364 9.4 APOA1 APOE
4 very-low-density lipoprotein particle GO:0034361 9.37 APOA1 APOE
5 endocytic vesicle lumen GO:0071682 9.32 APOA1 APOE
6 low-density lipoprotein particle GO:0034362 9.26 APOA1 APOE
7 chylomicron GO:0042627 9.16 APOA1 APOE
8 intermediate-density lipoprotein particle GO:0034363 8.96 APOA1 APOE
9 discoidal high-density lipoprotein particle GO:0034365 8.32 APOA1

Biological processes related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.58 APOA1 APOE
2 cholesterol metabolic process GO:0008203 9.58 APOA1 APOE
3 cholesterol homeostasis GO:0042632 9.57 APOA1 APOE
4 retinoid metabolic process GO:0001523 9.56 APOA1 APOE
5 triglyceride homeostasis GO:0070328 9.55 APOA1 APOE
6 triglyceride catabolic process GO:0019433 9.54 APOA1 APOE
7 cholesterol efflux GO:0033344 9.52 APOA1 APOE
8 lipoprotein metabolic process GO:0042157 9.51 APOA1 APOE
9 reverse cholesterol transport GO:0043691 9.49 APOA1 APOE
10 high-density lipoprotein particle remodeling GO:0034375 9.48 APOA1 APOE
11 high-density lipoprotein particle assembly GO:0034380 9.46 APOA1 APOE
12 phospholipid efflux GO:0033700 9.43 APOA1 APOE
13 chylomicron assembly GO:0034378 9.4 APOA1 APOE
14 positive regulation of cholesterol esterification GO:0010873 9.37 APOA1 APOE
15 chylomicron remodeling GO:0034371 9.32 APOA1 APOE
16 high-density lipoprotein particle clearance GO:0034384 9.26 APOA1 APOE
17 neuron projection regeneration GO:0031102 9.16 APOA1 APOE
18 regulation of Cdc42 protein signal transduction GO:0032489 8.96 APOA1 APOE
19 lipoprotein biosynthetic process GO:0042158 8.62 APOA1 APOE

Molecular functions related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.4 APOA1 APOE
2 beta-amyloid binding GO:0001540 9.37 APOA1 APOE
3 cholesterol binding GO:0015485 9.32 APOA1 APOE
4 lipid transporter activity GO:0005319 9.26 APOA1 APOE
5 cholesterol transporter activity GO:0017127 9.16 APOA1 APOE
6 lipoprotein particle binding GO:0071813 8.96 APOA1 APOE
7 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 8.62 APOA1 APOE

Sources for Cerebral Atherosclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....